US Stock MarketDetailed Quotes
CNSP CNS Pharmaceuticals
- 0.1150
- -0.0094-7.56%
Close Nov 25 16:00 ET
- 0.1165
- +0.0015+1.30%
Post 20:01 ET
6.61MMarket Cap-2P/E (TTM)
0.1240High0.1114Low6.63MVolume0.1230Open0.1244Pre Close772.05KTurnover11.75%Turnover Ratio0.00P/E (Static)57.49MShares114.500052wk High1.98P/B6.48MFloat Cap0.095552wk Low--Dividend TTM56.38MShs Float8534.8500Historical High--Div YieldTTM10.13%Amplitude0.0950Historical Low0.1160Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
CNS Pharmaceuticals Stock Forum
CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy
CNS Pharmaceuticals (NASDAQ:CNSP)presented updated results from its ongoing pivotal study comparing Berubicin versus Lomustine in adult patients with recurrent glioblastoma (GBM). The study has enrolled 239 patients, with comparable demographics between tr...
“Key financial metrics from the report indicate that CNS Pharmaceuticals significantly increased its cash and cash equivalents to over $6.9 million from $548,721 at the end of 2023.”
CNS Pharmaceuticals | 10-Q: Quarterly report
*nfa
CNS Pharmaceuticals: Financial Results and Strategic MovesS Makes Strategic Moves.
“In the latest earnings report for the quarter ended September 30, 2024, CNS Pharmaceuticals disclosed significant movements in its financial position, reflecting strategic efforts to bolster its pipeline and operational capabilities. The company reported a net loss of $5.6 million for the quarter, an improvement from the same period last year due to reduced research and developmen...
CNS Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Armistice Capital, LLC(3.20%),Steven Boyd(3.20%)
No comment yet